gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Excision repair cross-complementing rodent repair deficiency, complementation group 1

The product of this gene functions in the nucleotide excision repair pathway, and is required for the repair of DNA lesions such as those induced by UV light or formed by electrophilic compounds including cisplatin. The encoded protein forms a heterodimer with the XPF endonuclease (also known as ERCC4), and the heterodimeric endonuclease catalyzes the 5' incision in the process of excising the DNA lesion. The heterodimeric endonuclease is also involved in recombinational DNA repair and in the repair of inter-strand crosslinks. Mutations in this gene result in cerebrooculofacioskeletal syndrome, and polymorphisms that alter expression of this gene may play a role in carcinogenesis. Multiple transcript variants encoding different isoforms have been found for this gene. The last exon of this gene overlaps with the CD3e molecule, epsilon associated protein gene on the opposite strand. [provided by RefSeq, Oct 2009] (from NCBI)
Top mentioned proteins: HAD, XPD, CAN, rad1, XRCC1
Papers using ERCC1 antibodies
A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndrome.
Maizels Nancy, In PLoS Genetics, 1989
... ERCC1-His were used to transfect Sf9 insect cells, and to amplify the virus according to the manufacturer's instructions (BAC TO BAC system; Life Technologies).
Papers on ERCC1
Problems of variable biomarker evaluation in stratified medicine research-A case study of ERCC1 in non-small-cell lung cancer.
Billingham et al., Birmingham, United Kingdom. In Lung Cancer, Feb 2016
As a case study we evaluated how a particular predictive biomarker, ERCC1, was assessed in research on platinum-based chemotherapy in non-small-cell lung cancer and what motivated the choice of procedure.
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors.
Fazio et al., Milano, Italy. In Neuroendocrinology, Feb 2016
Ki67 labeling-index, grade of differentiation and excision-repair-cross-complementing group-1 (ERCC-1) were analyzed in tissue tumor samples.
Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
Bellmunt et al., Boston, United States. In Clin Genitourin Cancer, Jan 2016
Immunohistochemical analysis of the following DNA repair proteins was performed: ERCC1, RAD51, BRCA1/2, PAR, and PARP-1.
Factors affecting platinum sensitivity in cervical cancer.
Fukasawa et al., Tokyo, Japan. In Oncol Lett, Dec 2015
Each specimen was assessed for immunohistochemical expression of Ki-67, p53, B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), cleaved caspase-3, cyclooxygenase-2 (COX-2), and excision repair cross-complementation group 1 (ERCC1).
The ERCC1 and ERCC4 (XPF) genes and gene products.
Wood et al., United States. In Gene, Oct 2015
ERCC1-XPF is a core component of nucleotide excision repair and also plays a role in interstrand crosslink repair, some pathways of double-strand break repair by homologous recombination and end-joining, as a backup enzyme in base excision repair, and in telomere length regulation.
Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-Analysis.
Qiang et al., Nanjing, China. In Medicine (baltimore), Sep 2015
Excision repair cross complementing 1 (ERCC1) and xeroderma pigmentosum group D (XPD) play important roles in the nucleotide excision repair (NER) pathway.
Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.
Sørensen et al., Copenhagen, Denmark. In Eur Respir Rev, Jun 2015
A statistically significant prognostic impact was reported for: iNTR, TUBB3, RRM1, ERCC1, BRCA1, p53, MRP2, MSH2, TS, mucin, BAG-1, pERK1/2, pAkt-1, microRNA, TopIIA, 15-gene profile, 92-gene profile, 31-gene profile and 14-gene profile.
[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
Davydov et al., In Antibiot Khimioter, 2014
The review is concerned with the crucial marker of nucleotide excision repair ERCC1 and its contribution to platinum resistance of ovarian cancer.
DNA repair gene ERCC1 polymorphisms and glioma susceptibility among Chinese population: a meta-analysis.
Huang et al., Hangzhou, China. In Int J Clin Exp Med, 2014
BACKGROUND: Excision repair cross complementation group 1 (ERCC1) has been shown to be involved in the progression of glioma susceptibility.
Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
Zhu et al., Jinan, China. In Genet Mol Res, 2014
We performed a study to investigate the role of ERCC1 (rs11615, rs2298881, and rs3212986) and ERCC2 (rs13181, rs238406, and rs1799793) polymorphisms in the prognosis of gastric cancer.
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
Rosenberg et al., Boston, United States. In J Clin Oncol, 2014
Secondary end points included toxicity, disease-free survival (DFS), radiologic response (RaR), and biomarker correlates, including ERCC1.
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.
Soria et al., Caen, France. In J Clin Oncol, 2014
Excision repair cross-complementation group 1 (ERCC1) was shown to predict cisplatin-based chemotherapy response; EGFR mutations were predictive of epidermal growth factor receptor inhibition response.
DNA damage triggers a chronic autoinflammatory response, leading to fat depletion in NER progeria.
Garinis et al., Irákleion, Greece. In Cell Metab, 2013
Using mice carrying an ERCC1-XPF DNA repair defect systematically or in adipocytes, we show that DNA damage signaling triggers a chronic autoinflammatory response leading to fat depletion.
ERCC1 and MUS81-EME1 promote sister chromatid separation by processing late replication intermediates at common fragile sites during mitosis.
Rosselli et al., Villejuif, France. In Nat Cell Biol, 2013
To decipher the mechanisms protecting CFSs in G2/M, we searched for proteins that co-localize with FANCD2 on mitotic chromosomes, and identified XPF-ERCC1 and MUS81-EME1, two structure-specific endonucleases.
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Fischer et al., Detroit, United States. In J Clin Oncol, 2013
PURPOSE: We assessed whether chemotherapy selection based on in situ ERCC1 and RRM1 protein levels would improve survival in patients with advanced non-small-cell lung cancer (NSCLC).
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
Niedernhofer et al., Washington, D.C., United States. In Gynecol Oncol, 2012
ERCC1 mRNA levels in tumors correlated with outcome in patients with epithelial ovarian cancer treated with intraperitoneal cisplatin.
ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
Bruce et al., Stanford, United States. In Lung Cancer, 2012
Low expression of ERCC1 on circulating tumor cell (CTC) correlates with Progression-free survival (PFS) in patients with metastatic NSCLC receiving platinum-based therapy.
Fluorescence-based incision assay for human XPF-ERCC1 activity identifies important elements of DNA junction recognition.
McDonald et al., London, United Kingdom. In Nucleic Acids Res, 2012
XPF-ERCC1 has a preference for cleaving the phosphodiester bond positioned on the 3'-side of a T or a U, which is flanked by an upstream T or U suggesting that a T/U pocket may exist within the catalytic domain.
Multiple DNA binding domains mediate the function of the ERCC1-XPF protein in nucleotide excision repair.
Schärer et al., Stony Brook, United States. In J Biol Chem, 2012
Multiple DNA binding domains mediate the function of the ERCC1-XPF protein in nucleotide excision repair
ERCC1 expression in triple negative breast cancer.
Altundag et al., Ankara, Turkey. In J Buon, 2012
High ERCC1 expression is associated with triple negative breast cancer.
share on facebooktweetadd +1mail to friends